Acute Uveitis Following AstraZeneca COVID-19 Vaccination.
Ocul Immunol Inflamm
; : 1-4, 2023 Apr 06.
Article
in English
| MEDLINE | ID: covidwho-2254936
ABSTRACT
PURPOSE:
To report a case of bilateral acute uveitis following the first and subsequent doses of Oxford-AstraZeneca COVID-19 vaccination.METHOD:
A case report.RESULTS:
A 74-year-old Caucasian woman was presented with a one-day history of blurred vision, pain, photophobia, and redness in both eyes after receiving her first dose of the Oxford-AstraZeneca COVID-19 vaccine. Clinical evaluation confirmed bilateral anterior and intermediate uveitis six days later. Targeted diagnostic testing excluded infectious or autoimmune etiologies. After treatment with topical and oral corticosteroids, the patient had a resolution of symptoms with the recovery of visual function within seven weeks. Subsequently, she developed a recurrence of uveitis following the second dose of the Oxford-AstraZeneca COVID-19 vaccine, which required similar treatment, with slower tapering of corticosteroids over ten weeks. The patient had a full visual recovery.CONCLUSION:
Our case highlights the possibility of uveitis as an ocular complication of Oxford-AstraZeneca COVID-19 vaccination.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Diagnostic study
/
Etiology study
/
Experimental Studies
/
Prognostic study
Topics:
Vaccines
Language:
English
Journal:
Ocul Immunol Inflamm
Journal subject:
Allergy and Immunology
/
Ophthalmology
Year:
2023
Document Type:
Article
Affiliation country:
09273948.2023.2189456
Similar
MEDLINE
...
LILACS
LIS